New approaches in ovarian cancer based on genetics and carcinogenesis hypotheses (Review)

Mogos,Raluca Ana‑Μaria; Popovici,Razvan; Tanase,Adina Elena; Calistru,Tudor; Popovici,Paula; Grigore,Mihaela; Carauleanu,Alexandru

doi:10.3892/etm.2022.11351

New approaches in ovarian cancer based on genetics and carcinogenesis hypotheses (Review)

Authors:
- Raluca Ana‑Μaria Mogos
- Razvan Popovici
- Adina Elena Tanase
- Tudor Calistru
- Paula Popovici
- Mihaela Grigore
- Alexandru Carauleanu
View Affiliations

Affiliations: Department of Obstetrics and Gynaecology, ‘Cuza Voda’ Obstetrics and Gynaecology Clinical Hospital, 700038 Iasi, Romania, Obstetrics and Gynaecology, ‘Grigore T. Popa’ University of Medicine and Pharmacy, 700015 Iasi, Romania, PhD School, ‘Grigore T. Popa’ University of Medicine and Pharmacy, 700015 Iasi, Romania, Department of Pediatrics, ‘Grigore T. Popa’ University of Medicine and Pharmacy, 700015 Iasi, Romania
Published online on: May 4, 2022 https://doi.org/10.3892/etm.2022.11351
Article Number: 423

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer is the leading cause of death among gynecological malignancies and its incidence is rising in the last decades especially in developed countries. High‑grade serous ovarian cancer (HGSOC) represents 70% of ovarian cancers. Oral contraceptive use and salpingo‑oophorectomy or salpingectomy are well known protective factors against development of ovarian cancer. Identification of specific mutations associated with a high risk of developing ovarian cancer, especially BRCA1/2 mutation and TP53 mutations, has paved the way for implementation of new strategies for early diagnosis and therapy. Hereditary forms of ovarian cancer account for 5‑10% and have BRCA1/2 gene mutations or TP53 mutations. BRCA1/2 gene mutations appear in 22% of HGSOC and are associated with the defective homologous repair (HR)/DNA repair pathway. Genetic testing in ovarian cancer is important for risk assessment and therapeutic options. Although ‘universal genetic testing’ is not recommended yet, the procedure remains highly recommended in women with high risk. Genes involved in the development of ovarian cancer as TP53 may be targeted by gene therapy. Poly (ADP‑ribose) polymerase (PARP) inhibitors may enhance the cytotoxic effect of DNA‑damaging chemotherapy, and induce synthetic lethality in cases with BRCA1/2 mutations. Other strategies are designed to target pathways driven by various gene mutations, including the use of tyrosine kinase inhibitors in low‑grade serous ovarian cancer (LGSOC), or the use of drugs, which target growth factors, or epigenetic events including methylation, and acetylation of genes. The tubal involvement in ovarian carcinogenesis provides an important tool for the clinician to implement risk‑reducing strategies including salpingo‑oophorectomy or salpingectomy in high‑risk cases at appropriate ages.

View Figures

View References

1	Tripathi MK, Doxtater K, Keramatnia F, Zacheaus C, Yallapu MM, Jaggi M and Chauhan SC: Role of lncRNAs in ovarian cancer: Defining new biomarkers for therapeutic purposes. Drug Discov Today. 23:1635–1643. 2018.PubMed/NCBI View Article : Google Scholar
2	Reid BM, Permuth JB and Sellers TA: Epidemiology of ovarian cancer: A review. Cancer Biol Med. 14:9–32. 2017.PubMed/NCBI View Article : Google Scholar
3	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011.PubMed/NCBI View Article : Google Scholar
4	Pearce CL, Stram DO, Ness RB, Stram DA, Roman LD, Templeman C, Lee AW, Menon U, Fasching PA, McAlpine JN, et al: Population distribution of lifetime risk of ovarian cancer in the United States. Cancer Epidemiol Biomarkers Prev. 24:671–676. 2015.PubMed/NCBI View Article : Google Scholar
5	Sharma S, Raghav R, O'Kennedy R and Srivastava S: Advances in ovarian cancer diagnosis: A journey from immunoassays to immunosensors. Enzyme Microb Technol. 89:15–30. 2016.PubMed/NCBI View Article : Google Scholar
6	Lisio MA, Lili Fu, Goyeneche A, Gao Z and Telleria C: High-grade serous ovarian cancer: Basic sciences, clinical and therapeutic standpoints. Int J Mol Sci. 20(952)2019.PubMed/NCBI View Article : Google Scholar
7	Áyen A, Jiménez Martínez Y, Marchal JA and Boulaiz H: Recent progress in gene therapy for ovarian cancer. Int J Mol Sci. 19(1930)2018.PubMed/NCBI View Article : Google Scholar
8	Kim S, Wang M, Tyrer JP, Jensen A, Wiensch A, Liu G, Lee AW, Ness RB, Salvatore M, Tworoger SS, et al: A comprehensive gene-environment interaction analysis in ovarian cancer using genome-wide significant common variants. Int J Cancer. 144:2192–2205. 2019.PubMed/NCBI View Article : Google Scholar
9	Temkin SM, Bergstrom J, Samim Gi and Minasian L: Ovarian cancer prevention in high risk women. Clin Obstet Gynecol. 60:738–757. 2017.PubMed/NCBI View Article : Google Scholar
10	Kurman RJ and Shih IM: The dualistic model of ovarian carcinogenesis: Revisited, revised, and expanded. Am J Pathol. 186:733–747. 2016.PubMed/NCBI View Article : Google Scholar
11	Kurman RJ: Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Ann Oncol. 24 (Suppl 10):x16–x21. 2013.PubMed/NCBI View Article : Google Scholar
12	Rojas V, Hirshfield KM, Ganesan S and Rodriguez-Rodriguez L: Molecular characterization of epithelial ovarian cancer: Implications for diagnosis and treatment. Int J Mol Sci. 17(2113)2016.PubMed/NCBI View Article : Google Scholar
13	Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 474:609–615. 2011.PubMed/NCBI View Article : Google Scholar
14	Kim S, Han Y, Kim SI, Kim HS, Kim SJ and Song YS: Tumor evolution and chemoresistance in ovarian cancer. NPJ Precis Oncol. 2(20)2018.PubMed/NCBI View Article : Google Scholar
15	Toss A, Tomasello C, Razzaboni E, Contu G, Grandi G, Cagnacci A, Schilder RJ and Cortesi L: Hereditary ovarian cancer: Not only BRCA 1 and 2 genes. Biomed Res Int. 2015(341723)2015.PubMed/NCBI View Article : Google Scholar
16	Testa U, Petrucci E, Pasquini L, Castelli G and Pelosi E: Ovarian cancers: Genetic abnormalities, tumor heterogeneity and progression, clonal evolution and cancer stem cells. Medicines (Basel). 5(16)2018.PubMed/NCBI View Article : Google Scholar
17	Ezzati M, Abdullah A, Shariftabrizi A, Hou J, Kopf M, Stedman JK, Samuelson R and Shahabi S: Recent advancements in prognostic factors of epithelial ovarian carcinoma. Int Sch Res Notices. 2014(953509)2014.PubMed/NCBI View Article : Google Scholar
18	Shih IM and Kurman RJ: Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis. Am J Pathol. 164:1511–1518. 2004.PubMed/NCBI View Article : Google Scholar
19	Moufarrij S, Dandapani M, Arthofer E, Gomez S, Srivastava A, Lopez-Acevedo M, Villagra A and Chiappinelli KB: Epigenetic therapy for ovarian cancer: Promise and progress. Clin Epigenetics. 11(7)2019.PubMed/NCBI View Article : Google Scholar
20	Kroeger PT Jr and Drapkin R: Pathogenesis and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol. 29:26–34. 2017.PubMed/NCBI View Article : Google Scholar
21	Okamura H and Katabuchi H: Pathophysiological dynamics of human ovarian surface epithelial cells in epithelial ovarian carcinogenesis. Int Rev Cytol. 242:1–54. 2005.PubMed/NCBI View Article : Google Scholar
22	Nakamura M, Obata T, Daikoku T and Fujiwara H: The association and significance of p53 in gynecologic cancers: The potential of targeted therapy. Int J Mol Sci. 20(5482)2019.PubMed/NCBI View Article : Google Scholar
23	Erol A, Niemira M and Krętowski AJ: Novel approaches in ovarian cancer research against heterogeneity, late diagnosis, drug resistance, and transcoelomic metastases. Int J Mol Sci. 20(2649)2019.PubMed/NCBI View Article : Google Scholar
24	Mehra K, Mehrad M, Ning G, Drapkin R, McKeon FD, Xian W and Crum CP: STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis. Front Biosci (Elite Ed). E3:625–634. 2011.PubMed/NCBI View Article : Google Scholar
25	Cortez AJ, Tudrej P, Kujawa KA and Lisowska KM: Advances in ovarian cancer therapy. Cancer Chemother Pharmacol. 81:17–38. 2018.PubMed/NCBI View Article : Google Scholar
26	Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, et al: Whole-genome characterization of chemoresistant ovarian cancer. Nature. 521:489–494. 2015.PubMed/NCBI View Article : Google Scholar
27	Slomovitz B, Gourley C, Carey MS, Malpica A, Shih IM, Huntsman D, Fader AN, Grisham RN, Schlumbrecht M, Sun CC, et al: Low-grade serous ovarian cancer: State of the science. Gynecol Oncol. 156:715–725. 2020.PubMed/NCBI View Article : Google Scholar
28	Tarhriz V, Bandehpour M, Dastmalchi S, Ouladsahebmadarek E, Zarredar H and Eyvazi S: Overview of CD24 as a new molecular marker in ovarian cancer. J Cell Physiol. 234:2134–2142. 2019.PubMed/NCBI View Article : Google Scholar
29	Charbonneau B, Goode EL, Kalli KR, Knutson KL and DeRycke MS: The immune system in the pathogenesis of ovarian cancer. Crit Rev Immunol. 33:137–164. 2013.PubMed/NCBI View Article : Google Scholar
30	Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, Gille JJ, Jongsma AP, Pals G, Kenemans P and Verheijen RH: Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 195:451–456. 2001.PubMed/NCBI View Article : Google Scholar
31	Soong TR, Kolin DL, Teschan NJ and Crum CP: Back to the future? The fallopian tube, precursor escape and a dualistic model of high-grade serous carcinogenesis. Cancers (Basel). 10(468)2018.PubMed/NCBI View Article : Google Scholar
32	Weinberger V, Bednarikova M, Cibula D and Zikan M: Serous tubal intraepithelial carcinoma (STIC)-clinical impact and management. Expert Rev Anticancer Ther. 16:1311–1321. 2016.PubMed/NCBI View Article : Google Scholar
33	Vang R, Shih IeM and Kurman RJ: Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. Histopathology. 62:44–58. 2013.PubMed/NCBI View Article : Google Scholar
34	Finch A, Shaw P, Rosen B, Murphy J, Narod SA and Colgan TJ: Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol. 100:58–64. 2006.PubMed/NCBI View Article : Google Scholar
35	Gockley AA and Elias KM: Fallopian tube tumorigenesis and clinical implications for ovarian cancer risk-reduction. Cancer Treat Rev. 69:66–71. 2018.PubMed/NCBI View Article : Google Scholar
36	Daly MB, Pilarski R, Berry M, Buys SS, Farmer M, Friedman S, Garber JE, Kauff ND, Khan S, Klein C, et al: NCCN guidelines insights: Genetic/familial high-risk assessment: Breast and ovarian, version 2.2017. J Natl Compr Canc Netw. 15:9–20. 2017.PubMed/NCBI View Article : Google Scholar
37	Dubeau L: The cell of origin of ovarian epithelial tumours. Lancet Oncol. 9:1191–1197. 2008.PubMed/NCBI View Article : Google Scholar
38	Powell CB, Kenley E, Chen L, Crawford B, McLennan J, Zaloudek C, Komaromy M, Beattie M and Ziegler J: Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: Role of serial sectioning in the detection of occult malignancy. J Clin Oncol. 23:127–132. 2005.PubMed/NCBI View Article : Google Scholar